MERS-CoV as an emerging respiratory illness: A review of prevention methods
- PMID: 31730910
- PMCID: PMC7110694
- DOI: 10.1016/j.tmaid.2019.101520
MERS-CoV as an emerging respiratory illness: A review of prevention methods
Abstract
Introduction: Middle East Respiratory Coronavirus Virus (MERS-CoV) first emerged from Saudi Arabia in 2012 and has since been recognized as a significant human respiratory pathogen on a global level.
Methods: In this narrative review, we focus on the prevention of MERS-CoV. We searched PubMed, Embase, Cochrane, Scopus, and Google Scholar, using the following terms: 'MERS', 'MERS-CoV', 'Middle East respiratory syndrome' in combination with 'prevention' or 'infection control'. We also reviewed the references of each article to further include other studies or reports not identified by the search.
Results: As of Nov 2019, a total of 2468 laboratory-confirmed cases of MERS-CoV were diagnosed mostly from Middle Eastern regions with a mortality rate of at least 35%. A major outbreak that occurred outside the Middle East (in South Korea) and infections reported from 27 countries. MERS-CoV has gained recognition as a pathogen of global significance. Prevention of MERS-CoV infection is a global public health priority. Healthcare facility transmission and by extension community transmission, the main amplifier of persistent outbreaks, can be prevented through early identification and isolation of infected humans. While MERS-CoV vaccine studies were initially hindered by multiple challenges, recent vaccine development for MERS-CoV is showing promise.
Conclusions: The main factors leading to sustainability of MERS-CoV infection in high risk courtiers is healthcare facility transmission. MERS-CoV transmission in healthcare facility mainly results from laps in infection control measures and late isolation of suspected cases. Preventive measures for MERS-CoV include disease control in camels, prevention of camel to human transmission.
Keywords: Infection control; MERS-CoV; Outbreaks; Prevention; Saudi Arabia.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Comment in
-
Coronavirus 2019-nCoV: Is the genie already out of the bottle?Travel Med Infect Dis. 2020 May-Jun;35:101577. doi: 10.1016/j.tmaid.2020.101577. Epub 2020 Feb 7. Travel Med Infect Dis. 2020. PMID: 32044388 Free PMC article. No abstract available.
-
Remdesivir as a possible therapeutic option for the COVID-19.Travel Med Infect Dis. 2020 Mar-Apr;34:101615. doi: 10.1016/j.tmaid.2020.101615. Epub 2020 Mar 5. Travel Med Infect Dis. 2020. PMID: 32145386 Free PMC article. No abstract available.
-
Correspondence: Angiotensin-converting enzyme 2 coated nanoparticles containing respiratory masks, chewing gums and nasal filters may be used for protection against COVID-19 infection.Travel Med Infect Dis. 2020 Sep-Oct;37:101697. doi: 10.1016/j.tmaid.2020.101697. Epub 2020 Apr 23. Travel Med Infect Dis. 2020. PMID: 32335209 Free PMC article.
References
-
- Zaki A.M., Van Boheemen S., Bestebroer T.M., Osterhaus A.D.M.E., Fouchier R.A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials